SmartNuclide Raises ￥100M in Series B Financing

According to bioclub, SmartNuclide Biopharma ("SmartNuclide"), a company focused on the R&D of innovative drugs in nuclear medicine, announced the completion of its Series B financing of nearly 100 million yuan. This round is led by Ruihe Investment, with participation from Jiuyo Capital, Zhongyu Yingjia Health Investments, Xieyao Kexin Venture Capital, and others. 

Proceeds from the latest round will be mainly used to promote the current R&D projects, including the Phase III clinical trial and later commercialization of SNA001, the R&D of SNA002 both in China and the US, and the First-in-Human trial of SNA006, etc. Besides, SmartNuclide will also establish the core platform of radioactive drugs, enrich pipelines, and cooperate with international leading R&D institutions.

Founded in 2015, SmartNuclide Biopharma is a clinical-stage biopharmaceutical company focused on discovering and developing innovative biological drugs for molecular nuclear oncology, including both diagnostics and therapeutics. The company is committed to developing innovative pharmaceutical products in order to offer better treatment options to cancer patients.

The company has several products in development. The fastest product in the pipeline is SNA001 recombinant human thyrotropin (rhTSH), which can safely and rapidly increase the level of human serum thyrotropin and greatly reduce the pain caused by stopping thyroid hormone in patients with differentiated thyroid cancer before radioactive iodine treatment and during follow-up examination.

SmartNuclide has several products in development. SNA001 is a kind of recombinant human thyrotropin (rhTSH), which can safely and rapidly increase the level of human serum thyrotropin and greatly reduce the pain caused by stopping thyroid hormone in patients with differentiated thyroid cancer before radioactive iodine treatment and during follow-up examination. This product is in Phase III clinical trial and SmartNuclide has completed the first subject enrollment in April, which is expected to be the first rhTSH in mainland China.

Founded in 2010, Ruihe Investment is focused on equity investments in information technology, medicine, health, and cultural creativity.

Jiuyo Capital has strong background resources in the fields of private equity investment institutions, public funds, wealth companies, banks, trusts, investment banks, and brokerages. Jiuyo Capital is committed to building a more optimized and efficient investment industry ecosystem, and thus becomes China's most influential financial resource integration and service platform.